Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02490683 · ClinicalTrials.gov registry record · NA

Effects of Soy Based Dietary Supplements on Cardiometabolic Risk Factors.

A NA study, sponsored by Loma Linda University.

Completed
Registry status
NA
Development phase
24
Enrollment target

NCT02490683: Completed NA study, sponsored by Loma Linda University.

NCT02490683 is a NA study that has completed, run by Loma Linda University. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02490683, a NA study, has completed, sponsored by Loma Linda University.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target

Study Summary

This study will test the effect of both Luna Rich X© and Reliv Now© against placebo pills or powder (control) on blood lipids. It will also explore the potential effects of these dietary supplements on inflammation markers and other biological and anthropometric measures. The study intervention will be 30 weeks in length. Twenty four subjects with 2 or more cardiometabolic risk factors will be randomized to participate in the study.

Primary Outcome

Serum Low density cholesterol, high density cholesterol, apo Lipoprotein A and B, apo E allele genetic typing and triglycerides will be measured from the by performing lab tests.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Luna Rich X
  • DIETARY_SUPPLEMENT Reliv Now

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2015-10
Est. Completion 2016-05
Phase NA
Loma Linda University

237 total trials

What the finished NCT02490683 record still lists

NCT02490683 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02490683 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02490683 about?

NCT02490683 is a clinical study titled "Effects of Soy Based Dietary Supplements on Cardiometabolic Risk Factors.". This study will test the effect of both Luna Rich X© and Reliv Now© against placebo pills or powder (control) on blood lipids. It will also explore the potential effects of these dietary supplements on inflammation markers and other biological and anthropometric measures. The study intervention will...

What is the current status of trial NCT02490683?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2015-10. Estimated completion is 2016-05.

What interventions are being tested in trial NCT02490683?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Luna Rich X (DIETARY_SUPPLEMENT), Reliv Now (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02490683?

This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02490683's enrollment target sits among peer trials

24 1736th of 2000 higher than 246 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02490683, the US trial registry maintained by the National Library of Medicine. NCT02490683 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.